AIM ImmunoTech (AIM) Corporate presentation summary

Company overview

• Focuses on late-stage clinical immuno-pharma development for immuno-oncology, immune disorders, and viral diseases.

• Lead asset Ampligen is an immuno-modulator with broad-spectrum activity and positive clinical data.

• Active clinical programs target high-value indications, especially pancreatic and ovarian cancer.

• Collaborates with major pharma (AstraZeneca, Merck) and top research centers.

Ampligen mechanism and safety

• Ampligen is a TLR3 agonist that reprograms the tumor microenvironment and enhances immune response.

• Increases CTL infiltration and reduces Treg attraction, improving tumor immunogenicity.

• Demonstrates favorable safety profile with over 100,000 IV doses and >600 patient-years of exposure.

• Common adverse events are mild and transient; regulatory approvals in Argentina and early access in the Netherlands.

Intellectual property and market exclusivity

• Holds US and EU patents for Ampligen in combination with PD-L1 inhibitors, valid until 2039.

• Orphan Drug Designations provide 7–10 years of market exclusivity upon approval.